Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:17:19.712Z.
Calculation as of: 2026-10-06T14:17:19.712Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 15f4d798ccf4875796eb71b515450313e327808a34ea0284d87d2ac67ba5f97e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$7.31M
Price/FCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
Market Cap
$7.17M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.40M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.37M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Mangoceuticals, Inc. (MGRX)vs › | $7.21M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.17M | N/A | N/A | N/A | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.72M | N/A | N/A | N/A | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.83M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.91M | N/A | 6.05 | 13.36 | 13.36 |
| Aclarion, Inc. (ACON)vs › | $6.86M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.82M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
